Neramexane multiple unit dosage form

US8980318B2 · kind B2 · utility

Assignee

• Merz Pharma GmbH & Co. KGaA · DE

Inventors

• Bernhard Hauptmeier · Gelnhausen, DE
• Brigitte Purmann · Bad Hersfeld, DE

Key dates

• Filing date: Jun 22, 2011
• Grant date: Mar 17, 2015
• Expiry date: Jun 22, 2031

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Unit comprising neramexane, a pharmaceutically acceptable salt, solvate, conjugate, prodrug, polymorphic form, isomer, or derivative thereof; and a release-controlling excipient; wherein said unit has a diameter of from 0.1 to less than 6 mm.